Diagnosis and Treatment Approach

You have Stage 3b chronic kidney disease (CKD) with anemia of CKD, type 2 diabetes, subclinical hypothyroidism, and hyperkalemia—all of which require immediate, coordinated treatment to prevent cardiovascular complications and further kidney decline.

Primary Diagnoses

1. Chronic Kidney Disease (Stage 3b)

Your GFR of 35 mL/min/1.73 m² places you in CKD Stage 3b 1. The elevated BUN (34 mg/dL) and creatinine (1.46 mg/dL) confirm significant kidney dysfunction. The elevated alkaline phosphatase (192 U/L) suggests early mineral bone disease, a common CKD complication.

2. Anemia of CKD

Your hemoglobin of 8.7 g/dL with low MCH (25.1) and MCHC (28.2) indicates hypochromic microcytic anemia, characteristic of CKD-related anemia 2. The primary cause is insufficient erythropoietin production by your diseased kidneys 2. The elevated RDW (20.9) suggests additional contributing factors may be present, particularly iron deficiency.

3. Type 2 Diabetes (Suboptimally Controlled)

Your HbA1c of 7.3% indicates diabetes that requires better control 3, 1.

4. Subclinical Hypothyroidism

TSH of 6.49 mIU/L is elevated. Hypothyroidism is a recognized contributor to anemia in CKD and should be addressed 2. Research shows female patients and those with advanced CKD have higher rates of hypothyroidism, and overt hypothyroidism correlates with more severe anemia 4, 5.

5. Hyperkalemia (Critical)

Potassium of 6.0 mmol/L is moderate hyperkalemia requiring immediate attention 6.

Treatment Algorithm

IMMEDIATE PRIORITIES (Within 24-48 Hours)

A. Hyperkalemia Management

Dietary potassium restriction (avoid bananas, melons, orange juice, salt substitutes) 6
Review and adjust medications that raise potassium (NSAIDs, potassium supplements, certain antibiotics) 6
Monitor potassium within 2-4 weeks after any medication changes 7, 8
Consider loop diuretic if not already prescribed

B. Anemia Workup (Before Treatment)

You need additional testing before starting treatment:

Iron studies: Transferrin saturation (TSAT) and ferritin 2
- Target: TSAT >20% and ferritin >100 ng/mL before starting erythropoietin therapy 9
Complete blood count with reticulocyte count
Vitamin B12 and folate levels 2
Stool occult blood (to exclude GI bleeding) 2

FOUNDATIONAL THERAPIES (Start Within 1-2 Weeks)

1. Diabetes Management with Kidney Protection

Start an SGLT2 inhibitor immediately 1:

Recommended for T2D with CKD and eGFR ≥20 mL/min/1.73 m² (1A recommendation) 1
Choose agents with proven kidney/cardiovascular benefit (empagliflozin, dapagliflozin, or canagliflozin)
Continue even if eGFR drops below 20 once started 1, 7
Withhold during prolonged fasting, surgery, or acute illness 1, 8
May cause initial reversible eGFR decrease—this is NOT a reason to stop 8

Metformin dosing adjustment 1:

Reduce to 1000 mg daily maximum with your eGFR of 35 mL/min/1.73 m²
If already on metformin, adjust dose immediately

If HbA1c remains >7% after 3 months:

Add GLP-1 receptor agonist with proven cardiovascular benefit (semaglutide, dulaglutide, or liraglutide) 1

2. Blood Pressure and Kidney Protection

Start ACE inhibitor or ARB (if you have albuminuria, which needs checking) 1, 10, 7:

Titrate to maximum tolerated dose 10, 7, 8
Monitor creatinine and potassium within 2-4 weeks 7, 8
Continue therapy unless creatinine rises >30% within 4 weeks 7, 8
Do NOT combine ACE inhibitor with ARB—this is harmful 8

Critical caveat with your hyperkalemia:

ACE inhibitors/ARBs can worsen hyperkalemia 6, 7
Manage hyperkalemia with dietary restriction and other measures FIRST rather than avoiding these kidney-protective medications 7, 8
Only reduce dose or stop if hyperkalemia remains uncontrolled despite medical management 7, 8

3. Cardiovascular Protection

Start a statin 1:

Moderate-intensity statin recommended for all patients with diabetes and CKD (1A recommendation) 1
Examples: atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily

4. Hypothyroidism Treatment

Start levothyroxine replacement 2:

TSH >6.49 mIU/L warrants treatment, especially given your anemia 4, 5
Hypothyroidism contributes to anemia and treating it may improve hemoglobin response 5
Start low dose (25-50 mcg daily) and titrate based on TSH monitoring every 6-8 weeks
Target TSH: 0.5-2.5 mIU/L

ANEMIA TREATMENT (After Iron Studies Return)

If Iron Deficient (TSAT <20% or Ferritin <100 ng/mL):

Iron supplementation MUST precede or accompany erythropoietin therapy 2, 9:

Oral iron: 200 mg elemental iron daily (if tolerated and not on dialysis)
IV iron: More effective in CKD, especially if oral iron not tolerated
Recheck iron studies in 1-3 months

Erythropoiesis-Stimulating Agent (ESA):

Once iron replete and hypothyroidism treated 2:

Target hemoglobin: 11-12 g/dL (NOT higher—higher targets increase mortality risk) 11
Options: Epoetin alfa or darbepoetin alfa
Dosing individualized based on response
Monitor hemoglobin every 2-4 weeks initially

Common pitfall: Starting ESA without adequate iron stores leads to poor response 9. Always ensure iron sufficiency first.

MONITORING SCHEDULE

Within 2-4 weeks:

Potassium, creatinine, BUN (after starting/adjusting ACE inhibitor or ARB) 7, 8
Blood pressure

Every 1-3 months:

Complete metabolic panel (potassium, creatinine, calcium, phosphate)
Hemoglobin (if on ESA, check every 2-4 weeks initially)
HbA1c (every 3 months)
Iron studies (if on iron supplementation)

Every 6-8 weeks:

TSH (until stable on levothyroxine)

Every 6-12 months:

Lipid panel
Urine albumin-to-creatinine ratio (ACR)—you need this checked to guide ACE inhibitor/ARB use 1
Parathyroid hormone (PTH), vitamin D (for mineral bone disease monitoring)

Key Clinical Pitfalls to Avoid

Do NOT aim for "normal" hemoglobin with ESA—target 11-12 g/dL only 11
Do NOT start ESA before correcting iron deficiency and hypothyroidism 2, 5, 9
Do NOT stop ACE inhibitor/ARB for mild hyperkalemia—manage potassium medically first 7, 8
Do NOT combine ACE inhibitor + ARB—increases harm without benefit 8
Do NOT delay SGLT2 inhibitor—this is the single most important medication for slowing CKD progression in diabetes 1
Do NOT continue full-dose metformin—reduce to ≤1000 mg daily at your eGFR 1

Why This Matters for Your Outcomes

Untreated, your constellation of problems significantly increases risk of:

Cardiovascular events (heart attack, stroke, heart failure) 2, 1
Progression to dialysis 1
Hospitalizations 9
Premature death 2, 11

With comprehensive treatment, you can:

Slow or halt CKD progression 1
Reduce cardiovascular risk by 30-40% 1
Improve quality of life through anemia correction 2, 11
Potentially delay or avoid dialysis 1

Have a follow-up question?